Porovnat metody
Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.
| PASI (Psoriasis Area and Severity Index)× | EASI (Eczema Area and Severity Index)× | |
|---|---|---|
| Obor | Dermatologie | Dermatologie |
| Rodina | Process / pipeline | Process / pipeline |
| Rok vzniku≠ | 1978 | 2001 |
| Tvůrce≠ | Fredriksson T, Pettersson U | Hanifin JM, Thurston M |
| Typ | Clinician-rated | Clinician-rated |
| Původní zdroj≠ | Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. DOI ↗ | Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI ↗ |
| Další názvy | PASI Index | EASI Index |
| Příbuzné | 2 | 2 |
| Shrnutí≠ | The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies. | The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA). |
| ScholarGateDatová sada ↗ |
|
|